Materials • Major Chemicals
$79.55 ▲ +1.54
(+1.97%)
MKT CAP: $6.02B • VOL: 1.75M
52W L $67 52W H $112
HXL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.89B | $1.90B | $1.79B |
| YoY Revenue Growth % | -0.5% | +6.4% | — |
| Gross Profit | $434.8M | $469.8M | $787.2M |
| Gross Margin % | 23.0% | 24.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $171.6M | $186.1M | $215.3M |
| Operating Margin % | 9.1% | 9.8% | 12.0% |
| Net Income (GAAP) | $109.4M | $132.1M | $105.7M |
| EBITDA (Normalized) | $230.2M | $255.7M | $279.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $230.5M | $289.9M | $257.1M |
| Capital Expenditures (CapEx) | $73.3M | $87.0M | $80.5M |
| Free Cash Flow (FCF) | $157.2M | $202.9M | $176.6M |
| FCF Margin % | 8.3% | 10.7% | 9.9% |
| Return on Invested Capital (ROIC %) | 6.2% | 7.0% | 8.5% |
| Cash & Short-Term Equivalents | $71.0M | $125.4M | $364.3M |
| Total Debt (Short + Long Term) | $993.0M | $700.6M | $775.0M |
| Total Stockholders' Equity | $1.25B | $1.53B | $1.59B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HXL.